Otonomy 2018 First Quarter Financial Results

[beeeep]

Otonomy posted their 1st quarter financial results today.
I think most of the stuff in there is already known, however, it gives a nice short summary about their drug pipeline.

http://investors.otonomy.com/news-r...orts-first-quarter-2018-financial-results-and

OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in development for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. The company expects to initiate a Phase 1/2 clinical trial in hearing loss patients in the first half of 2019.
OTO-5XX is an otoprotectant in development for the prevention of cisplatin-induced hearing loss.
OTO-6XX induces hair cell regeneration and is being developed for the treatment of severe hearing loss.

Developing OTO-313 for the Treatment of Tinnitus: Gacyclidine is a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist that has been evaluated in a Phase 1 clinical safety trial, with no safety concerns observed. The company expects to initiate a Phase 1/2 clinical trial for OTO-313, an improved formulation of gacyclidine, in tinnitus patients in the first half of 2019.
[...]
In second half of 2018, select a candidate for clinical development for both OTO-5XX and OTO-6XX hearing loss programs.

In first half of 2019, initiate a Phase 1/2 clinical trial of OTO-313 in tinnitus patients.

In first half of 2019, initiate a Phase 1/2 clinical trial of OTO-413 in hearing loss patients.

Also, they actually started to earn (a little) money:

Revenue: Net sales of OTIPRIO totaled $0.3 million for the first quarter of 2018.

 

[JohnAdams]

I also like their logo.

http://www.otonomy.com/pipeline/product-candidates/

 

[PDodge]

Imma sit here and watch it move

 

[JohnAdams]

Their products look horrible. The tinnitus drug is in a class of drugs called a dissociative. Look that up. I think I'd rather have tinnitus then take that crap. This just reinforces my belief that big pharma is a big pile of poop.

 

[jacob21]

https://globenewswire.com/news-rele...O-413-Presentation-Selected-as-Hot-Topic.html

 

[Paulmanlike]

They still haven't said if OTO-313 is for chronic or acute tinnitus. Anybody know what it's aimed for?

How about Auris Medical's AM-102?

 

[katri]

At least they are combining the phases with OTO-413

 

[Manny]

At least they are combining the phases with OTO-413

"...We are also excited to advance OTO-413 into clinical trials next year for patients with speech-in-noise hearing difficulties, and expect that this will be the first such trial evaluating a potential treatment for cochlear synaptopathy."
I think this could still mean they're only evaluating for safety. :/

 

[katri]

"...We are also excited to advance OTO-413 into clinical trials next year for patients with speech-in-noise hearing difficulties, and expect that this will be the first such trial evaluating a potential treatment for cochlear synaptopathy."
I think this could still mean they're only evaluating for safety. :/

Of course. But it is a "potential treatment". That means that they want it to be a treatment. If there are positive results and they feel like they are viable then it's good news.

 

[Manny]

Of course. But it is a "potential treatment". That means that they want it to be a treatment. If there are positive results and they feel like they are viable then it's good news.

Gotcha. I was commenting on the phase combination/separation thing.

 

[katri]

@Manny
Oh, I see what you're saying. I'm not terribly worried tho. Otonomy sucks so much that they will take the wins wherever they can. At this point, they can't afford to just conduct random research assignments without a means to an end (or drug). Out of all of their hearing loss trials, I think this is the best one. I just want to find a patent or something.